Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Warner Chilcott
This study is designed to evaluate the safety and efficacy of 4.8 g/day using 800 mg Asacol tablets as compared to 2.4g/day using 400 mg Asacol tablets in newly- and previously-diagnosed patients who are experiencing a flare-up of mildly to moderately active ulcerative colitis.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
confirmed diagnosis of ulcerative colitis
You may not be if
a history of allergy or hypersensitivity to salicylates or aminosalicylates;
